Tatva Chintan Pharma Chem Ltd (NSE: TATVA, BSE: 543321) is a Vadodara, Gujarat-based company in the Custom Synthesis and Specialty CDMO industry. With a market capitalisation of ₹3,871 Cr, it ranks #954 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 13 in Custom Synthesis and Specialty CDMO. At ₹1,676.20 (as of 16 Nov 2026), the share price is 20.7% below its 52-week high of ₹2,113.60 and 60.5% above its 52-week low of ₹1,044.10. The share price is up 12.2% over one year and down 1.6% over three months.
| Current Price | ₹1,676.20 |
|---|---|
| Market Cap | ₹3,871 Cr |
| NSE Symbol | TATVA |
| BSE Code | 543321 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Custom Synthesis and Specialty CDMO |
| P/E Ratio | 92.5 |
| Return on Equity | 5.53% |
| Return on Assets | 4.01% |
| 52-Week Range | ₹1,044.10 – ₹2,113.60 |
| 1-Year Price Change | +12.2% |
| 3-Month Price Change | -1.6% |
| Beta (1Y) | 0.34 |
| Dividend Yield | 0.12% |
| Headquarters | Vadodara, Gujarat |
| Website | www.tatvachintan.com |
| Revenue | ₹217 Cr |
|---|---|
| Net Profit | ₹21 Cr |
| Net Margin | 9.9% |
| EPS (Basic) | ₹9.17 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Tatva Chintan Pharma Chem Ltd reported revenue of ₹217 Cr in Q2 FY27, up 75.9% from ₹124 Cr in Q2 FY26 and up 30.1% from ₹167 Cr in Q1 FY27. It posted a net profit of ₹21 Cr for the quarter, against a net profit of ₹10 Cr in Q2 FY26 (up 116.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹108 Cr (Q4 FY25) to ₹217 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹217 Cr | ₹21 Cr | 9.9% |
| Q1 FY27 | ₹167 Cr | ₹16 Cr | 9.6% |
| Q4 FY26 | ₹134 Cr | ₹10 Cr | 7.7% |
| Q3 FY26 | ₹131 Cr | ₹15 Cr | 11.6% |
| Q2 FY26 | ₹124 Cr | ₹10 Cr | 8.0% |
| Q1 FY26 | ₹117 Cr | ₹7 Cr | 5.7% |
| Q4 FY25 | ₹108 Cr | ₹1 Cr | 1.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 72.02% of Tatva Chintan Pharma Chem Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 40.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
1. Manufacturing of Chemicals-This segment manufactures and sells specialty chemicals.
1. Specialty Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Anupam Rasayan India Ltd | ₹13,570 Cr | 79.6 | 5.76% | ₹806 Cr | +20.1% |
| Neogen Chemicals Limited (Neogen) | ₹8,322 Cr | 259.2 | 3.58% | ₹296 Cr | +93.4% |
| Prasol Chemicals Limited | ₹4,681 Cr | 58.1 | — | ₹413 Cr | — |
| Laxmi Organic Industries Ltd | ₹4,574 Cr | 57.2 | 4.08% | ₹1,083 Cr | -18.9% |
| Tatva Chintan Pharma Chem Ltd | ₹3,871 Cr | 92.5 | 5.53% | ₹217 Cr | +12.2% |
| Paushak Ltd. | ₹1,487 Cr | 38.1 | 8.22% | ₹89 Cr | — |
| Sunshield Chemicals Ltd. | ₹833 Cr | 25.2 | 17.02% | — | +12.6% |
| Chemcon Speciality Chemicals Limited | ₹733 Cr | 31.8 | 4.80% | ₹65 Cr | -12.8% |
| Resonance Specialties Ltd. | ₹327 Cr | 31.5 | 15.15% | — | +203.4% |
Listed by market capitalisation. Ratios are shown for context only.
Tatva Chintan Pharma Chem Ltd is trading at ₹1,676.20, with a market capitalisation of ₹3,871 Cr.
Tatva Chintan Pharma Chem Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Custom Synthesis and Specialty CDMO).
Tatva Chintan Pharma Chem Ltd has a P/E of 92.5 and a return on equity of 5.53%.
Tatva Chintan Pharma Chem Ltd is listed on the NSE under the symbol TATVA and on the BSE under the scrip code 543321.
Tatva Chintan Pharma Chem Ltd's share price is up 12.2% over one year and down 1.6% over three months. Its 52-week range is ₹1,044.10 to ₹2,113.60.
In Q2 FY27, Tatva Chintan Pharma Chem Ltd reported revenue of ₹217 Cr and net profit of ₹21 Cr, with basic EPS of ₹9.17 (consolidated, parsed from the company's exchange filing).
Tatva Chintan Pharma Chem Ltd reported revenue of ₹217 Cr in Q2 FY27, up 75.9% from ₹124 Cr in Q2 FY26 and up 30.1% from ₹167 Cr in Q1 FY27.
Promoters held 72.02% of Tatva Chintan Pharma Chem Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.